The DOI matches its Crossref record.
Tolvaptan inhibits ERK-dependent cell proliferation, Cl−secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin
Open accessAbstract
In autosomal dominant polycystic kidney disease (ADPKD), arginine vasopressin (AVP) accelerates cyst growth by stimulating cAMP-dependent ERK activity and epithelial cell proliferation and by promoting Cl−-dependent fluid secretion. Tolvaptan, a V2 receptor antagonist, inhibits the renal effects of AVP and slows cyst growth in PKD animals. Here, we determined the effect of graded concentrations of tolvaptan on intracellular cAMP, ERK activity, cell proliferation, and transcellular Cl−secretion using human ADPKD cyst epithelial cells. Incubation of ADPKD cells with 10−9 M AVP increased intracellular cAMP and stimulated ERK and cell proliferation. Tolvaptan caused a concentration-dependent inhibition of AVP-induced cAMP production with an apparent IC 50 of ∼10−10 M. Correspondingly, tolvaptan inhibited AVP-induced ERK signaling and cell proliferation. Basolateral application of AVP to ADPKD cell monolayers grown on permeable supports caused a sustained increase in short-circuit current that was completely blocked by the Cl−channel blocker CFTR inh-172, consistent with AVP-induced transepithelial Cl−secretion. Tolvaptan inhibited AVP-induced Cl−secretion and decreased in vitro cyst growth of ADPKD cells cultured within a three-dimensional collagen matrix. These data demonstrate that relatively low concentrations of tolvaptan inhibit AVP-stimulated cell proliferation and Cl−-dependent fluid secretion by human ADPKD cystic cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205511 · Cited by 1,614
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Perrone, R. D., Koch, G., Ouyang, J., McQuade, R. D., Blais, J. D., Czerwiec, F. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1710030 · Cited by 639
Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease
Cruz, N. M., Song, X., Czerniecki, S. M., Gulieva, R. E., Churchill, A. J., Kim, Y. K., Winston, K., Tran, L. M., Diaz, M. A., Fu, H., et al. (2017) · Nature Materials · doi:10.1038/nmat4994 · Cited by 291
Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease
Torres, V. E., & Harris, P. C. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040398 · Cited by 289
Vasopressin: a novel target for the prevention and retardation of kidney disease?
Bankir, L., Bouby, N., & Ritz, E. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.22 · Cited by 214
Metadata
- Authors
- Reif, G. A., Yamaguchi, T., Nivens, E., Fujiki, H., Pinto, C. S., & Wallace, D. P.
- Venue
- American Journal of Physiology-Renal Physiology
- Publisher
- American Physiological Society
- Published
- 2011-11
- Volume
- 301
- Issue
- 5
- Pages
- F1005-F1013
- ISSN
- 1522-1466 (ISSN-L)
- 1931-857X
- OpenAlex
- W2154921342
- Cited by
- 160
- References
- 0
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tolvaptan inhibits ERK-dependent cell proliferation, Cl−secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. https://app.cochat.ai/papers/10.1152/ajprenal.00243.2011
- The paper
- Reif, G. A., Yamaguchi, T., Nivens, E., Fujiki, H., Pinto, C. S., & Wallace, D. P. (2011). Tolvaptan inhibits ERK-dependent cell proliferation, Cl−secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. American Journal of Physiology-Renal Physiology. https://doi.org/10.1152/ajprenal.00243.2011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.